Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based Circulating Tumor DNA Assays,...

Area of Science:

• Oncology
• Molecular Diagnostics
• Biomarker Development

Background:

• Circulating tumor DNA (ctDNA) is a crucial biomarker for cancer management.
• Liquid biopsy assays using next-generation sequencing (NGS) are increasingly used for ctDNA detection.
• Rigorous analytical validation (AV) is essential for clinical adoption and regulatory approval of these assays.

Purpose of the Study:

• To present the updated version 2.0 of the BLOODPAC generic AV protocols for ctDNA liquid biopsy assays.
• To outline the feedback process, challenges, and changes incorporated into the revised protocols.
• To ensure continued relevance, usability, and scientific rigor of AV protocols for diagnostic developers.

Main Methods:

• Development of initial generic AV protocols by the BLOODPAC AV Working Group in 2020.
• Gathering user feedback through an open comment period (April-July 2023) from nine institutions.
• Reviewing aggregated feedback with input from the US Food and Drug Administration (FDA) presubmission process.

Main Results:

• Identification of key challenges and user-reported issues with the initial protocols.
• Incorporation of feedback to enhance the practicality and scientific robustness of the protocols.
• Release of version 2.0 of the BLOODPAC generic AV protocols, reflecting current technologies and user needs.

Conclusions:

• The updated BLOODPAC AV protocols (version 2.0) provide a refined framework for validating ctDNA liquid biopsy assays.
• The revision process ensures the protocols remain aligned with evolving technologies and regulatory expectations.
• These standardized protocols aim to facilitate regulatory approval, market entry, and improved cancer patient outcomes.